-
-
-
-
-
-
-
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
-
-
-
-
-
-
-
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in TransMedics Group, Inc of Class Action Lawsuit and Upcoming Deadlines - TMDX
-
-
-
-
-
-
-
TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on TransMedics Group (TMDX)
-
-
-
-
-
-
-
TransMedics Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Hercules Capital Reports Second Quarter 2019 Financial Results
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

